pharma QA – Page 98 – Pharma.Tips

Pet Failure for multi-dose products: how to avoid repeat 483 observations

Addressing Pet Failures in Multi-Dose Products to Reduce 483 Observations Pet failures—the term used for product failures in multi-dose formats—can lead to significant regulatory scrutiny and operational inefficiencies. Such failures…

Aseptic Gowning Deviation after maintenance intervention: FDA/MHRA investigation narrative and batch impact

Aseptic Gowning Deviation Investigation Following Maintenance Activities Aseptic conditions are critical in the manufacturing of parenteral dosage forms. Any deviation, especially after maintenance interventions, can lead to significant ramifications, including…

Em Excursion In Grade A after maintenance intervention: FDA/MHRA investigation narrative and batch impact

Managing Em Excursion In Grade A Zones Following Maintenance Interventions In pharmaceutical manufacturing, particularly within sterile environments, deviations from established Grade A conditions can pose significant risks to product quality…

Ccit Failure in eye drop manufacturing: packaging integrity and CCIT justification

Understanding Ccit Failure in Eye Drop Manufacturing: Addressing Packaging Integrity and Justification The integrity of packaging is paramount in the pharmaceutical industry, particularly for ophthalmic products like eye drops, where…

Em Excursion In Grade A during campaign changeover: CAPA package with evidence and effectiveness checks

Investigating Em Excursion in Grade A Environments During Changeover Campaigns Manufacturing pharmaceuticals in a Grade A environment is critical, particularly for parenteral dosage forms where sterility is paramount. An excursion…

Ccit Failure during hold-time study: risk assessment for patient safety and recall

Investigation of Ccit Failure during Hold-Time Study: Ensuring Patient Safety and Compliance A holding time study is critical in pharmaceutical manufacturing, particularly for parenteral dosage forms, as it assesses the…

E&L Failure at stability pull: packaging integrity and CCIT justification

Examining E&L Failure During Stability Pull: Assessing Packaging Integrity and CCIT Justification In the realm of pharmaceutical manufacturing, the advent of a failure in extractables and leachables (E&L) testing during…

Particulate Matter Oos during terminal sterilization: data integrity checks for lab and shop floor

Understanding and Investigating Particulate Matter OOS During Terminal Sterilization During terminal sterilization of injectable products, the presence of particulate matter can trigger Out of Specification (OOS) results, posing significant compliance…

Smoke Study Failure during terminal sterilization: data integrity checks for lab and shop floor

Addressing Failures in Smoke Studies During Terminal Sterilization: A Comprehensive Investigation Approach In pharmaceutical manufacturing, the reliability of sterilization processes is critical, particularly for parenteral dosage forms. A smoke study…

Sterility Test Failure in eye drop manufacturing: risk assessment for sterility assurance

Sterility Test Failures in the Manufacturing of Eye Drops: An Investigation Approach Sterility test failures in eye drop manufacturing present significant risks that can compromise product quality and patient safety.…

Particulate Matter Oos post-sterile filtration: risk assessment for patient safety and recall

Assessing Particulate Matter OOS After Sterile Filtration: An Investigation for Safety and Compliance In the pharmaceutical industry, maintaining a sterile environment is paramount, especially when producing injectable products. A situation…

Filter Integrity Failure during terminal sterilization: risk assessment for patient safety and recall

Investigating Filter Integrity Failures in Terminal Sterilization: Assessing Risks in Pharmaceutical Manufacturing In the pharmaceutical manufacturing environment, a filter integrity failure during terminal sterilization can pose significant risks to product…